Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Rare Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LAMB3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LAMB3 Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. Available in monomeric and truncated formats. |
View LAMB3 Products |
| Gene Delivery | LAMB3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Ideal for cell-based adhesion and migration assays. |
View LAMB3 Products |
| Benchmark Ab | Anti-LAMB3 Recombinant Antibody Recombinant positive control antibody. Sequence verified for consistent performance in ELISA and FACS. |
View LAMB3 Products |
| Validator | LAMB3 siRNA Set Target-specific knockdown pool for functional validation and specificity assays. |
View LAMB3 Products |
| Related Target A | LAMA3 (Laminin Subunit Alpha-3) Partner subunit in the heterotrimeric Laminin-332 complex. Essential for physiological assembly and receptor-binding assays. |
View LAMA3 Products |
| Related Target B | LAMC2 (Laminin Subunit Gamma-2) The third component of the Laminin-332 heterotrimer. Critical for complete extracellular matrix reconstruction. |
View LAMC2 Products |
| Related Target C | ITGB4 (Integrin Beta-4) Primary cellular receptor for Laminin-332. Crucial for cell adhesion and downstream signaling validation. |
View ITGB4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Laminin Subfamily Off-target Screening | High-purity human LAMB1, LAMB2, and LAMB3 ortholog proteins available with >95% purity to eliminate cross-reactivity. |
| Conformational Integrity in Cell Assays | Lentivirus-mediated stable cell expression preserves native heterotrimeric assembly on the cell surface. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live LAMB3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LAMB3 therapeutics is intensifying, with major players shifting focus from traditional gene therapies to targeted oncology modalities. LAMB3 (Laminin Subunit Beta-3) is historically known for its role in Junctional Epidermolysis Bullosa (JEB), where gene-corrected epidermal stem cell therapies have led the way. However, the next wave of R&D is rapidly targeting LAMB3 overexpressing solid tumors, including pancreatic ductal adenocarcinoma, lung squamous cell carcinoma, and gastric cancers, where LAMB3 drives epithelial-to-mesenchymal transition (EMT) and metastasis.
Developing effective therapeutics requires highly specific reagents. Because LAMB3 is a secreted extracellular matrix glycoprotein that functions primarily within the heterotrimeric Laminin-332 complex, screening requires precise recombinant proteins that preserve native post-translational modifications, alongside robust cell-based expression systems to model physiological interactions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (Lentiviral/Retroviral) | Holostem, Krystal Biotech | Junctional Epidermolysis Bullosa (JEB) | Expression Validation (Need high-titer Lentivirus & Western Blot validated controls) |
| Monoclonal Antibodies (mAbs) | Academic Institutions, Biotech Startups | Solid Tumors (Pancreatic, Gastric) | Epitope Mapping & Blockade (Need native HEK293-expressed LAMB3 monomer/complex) |
| Antibody-Drug Conjugates (ADCs) | Oncology-focused Biopharma | Squamous Cell Carcinomas, EMT-driven Tumors | Internalization Assay (Need high-purity, low-endotoxin ECD-Fc fusion proteins) |